Zejuan Li Lab

6887

Citations

37

h-index

About the Lab

The Li lab is interested in understanding the pathological mechanisms underlying the development of leukemia and lymphoma and uses advanced in vitro and in vivo techniques to interrogate the functional roles of protein-coding and non-coding genes in these diseases. The lab is also interested in identifying novel genetic and epigenetic biomarkers for diagnosis, prognosis, and therapeutic response prediction in leukemia, lymphoma, and solid tumors. Dr. Li's research has been published in high-impact journals, including Cancer Cell, Journal of Clinical Oncology, Nature Communications, Blood, Leukemia, Proceedings of the National Academy of Science, Genome Research, and Cancer Research.

Dr. Li is the Co-Director of the Houston Methodist Hospital Molecular Diagnostic Laboratory and an Associate Professor in the Department of Pathology and Genomic Medicine at the Houston Methodist Academic Institute and Weill Cornell Medical College. Prior to joining Houston Methodist in 2018, she was an Assistant Professor of Human Genetics and an Assistant Director of the Molecular Diagnostic Laboratory at the University of Chicago. Dr. Li is board certified in Clinical Molecular Genetics by the American Board of Medical Genetics and Genomics and has received awards and funding from several agencies, including the American Cancer Society, Leukemia & Lymphoma Society, and Gabrielle’s Angel Foundation for Cancer Research.
Pathology News
There’s a New Strep in Town
New study highlights the complexity of human infections caused by a rapidly emerging strep subtype
Improving Vaccine Design with an AI Booster

CEPI awards $34 million to the Houston Methodist Research Institute-led consortium to use artificial intelligence for the design of vaccines to fight diseases with pandemic potential.

Omicron – Ongoing Lessons in a Pandemic

Omicron Demonstrates the Power and Necessity of Genetic Sequencing in a Pandemic

Researchers Uncover Distinct Patterns of a Common Pathology in Dementia

Known as LATE, a very common form of brain pathology affects ~40% of elderly patients. Researchers at Houston Methodist have unraveled several patterns of LATE in the brains of aging and demented patients. These patterns have distinct clinical, pathologic and genetic associations.

Fighting a Deadly Duo
Investigating therapeutics to fight deadly TB/HIV coinfections.
Houston Methodist and Purdue University Make a Breakthrough That May Result in a More Effective Tuberculosis Vaccine

A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice

Donate to Houston Methodist

With your support, Houston Methodist provides exceptional research, education, and care that is truly leading medicine.

Donate Now